OHSU

Tomasz M. Beer, M.D., F.A.C.P.

Head Shot of Tomasz Beer
Email: 
click here
Office: 
503 494-6594

Background

Dr. Beer’s major research interests include clinical trials, preclinical investigation and risk factors in prostate cancer. His program investigates a broad range of novel agents for prostate cancer, including immune therapies, nutritional supplements, hormonal agents, chemotherapy drugs and target biologic drugs that seek to exploit prostate cancer’s unique vulnerabilities.

Dr. Beer’s clinical research program is tightly linked with laboratory investigations designed to reveal new treatment targets and strategies.


Summary of Current Research

Special Interests:

Hematology and Medical Oncology

Prostate Cancer


Selected Publications

"Sequencing therapy in advanced prostate cancer: Focus on sipuleucel-T," Expert Review of Anticancer Therapy (Vol: 14, Issue: 1, Page 51-61) - 2014

"Skeletal response to resistance and impact training in prostate cancer survivors," Medicine and Science in Sports and Exercise - 2014

"A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer," Urologic Oncology: Seminars and Original Investigations (Vol: 31, Issue: 5, Page 581-588) - 2013

"Cancer clinical trials of tomorrow," Scientist (Vol: 27, Issue: 4, ) - 2013

"Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: A case report with implications for future research," Urology (Vol: 81, Issue: 2, Page 381-383) - 2013

 

Back to faculty list

OHSU Knight Cancer Institute

Visit Our Site

For Healthcare Professionals


Contact

  Email Tomasz Beer

503 494-6594

Memberships & Associations

American College of Physicians Oregon Medical Association American Society of Clinical Oncology American Society of Hematology American Association for Cancer Research Southwest Oncology Group American Urological Association Radiation Therapy Oncology Group